All Blogs
Mar 06, 2024
Major Highlights and Insights from the AAAAI Annual Meeting, 2024
American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 annual meeting, is the premier educational event for allergists/immunologists around the world that was held from February 23 to 26 at the Walter E. Washington Convention Center this year. The American Academy of Allergy, Asthma & Immunology (AAA...
Read More...
Mar 05, 2024
Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis
Acoramidis Joins Bayer's Robust Lineup, Boosting Cardiology Solutions Bayer has obtained the exclusive rights to market acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH, and BridgeBio Europe B.V. Acoramidis, a highly potent and selective small molecule given orally, functions as a ...
Read More...
Mar 04, 2024
Gene Therapies as a Game-Changer in Ophthalmology: Eyeing the Future
Gene therapy is becoming a promising solution for retinal degenerative illnesses, particularly because the retina offers an excellent avenue for studying and treating eye-related issues. Importantly, it is the first tissue in the United States to receive approval for gene therapy in cases of inherited disorders. ...
Read More...
Mar 01, 2024
Revolutionizing the Food Allergy Treatment: The Impact of Xolair’s Approval
Individuals suffering from food allergies now have access to a medication that can potentially avert serious consequences. This medication, which has been available for twenty years, has received approval from the FDA. Xolair (omalizumab) by Roche and Novartis is the first food allergy treatment sanctioned to dimin...
Read More...
Feb 29, 2024
Profound Medical and Siemens Entered Into a Collaboration; CardiAI and Carleton University Forged an Innovative Partnership; BrainMD Launched Revolutionary Smart Collagen Supplements; FDA Approved Seastar’s Quelimmune Device; Nebraska-developed Surgical Robot Received FDA Approval; Catheter Precision Presentated First Clinical Data on LockeT
Profound Medical and Siemens Healthineers Entered Into a Collaboration on Ultrasound Ablation On February 27, 2024, Profound Medical entered into a non-exclusive agreement with Siemens Healthineers. The objective of the agreement was to establish the foundation for Profound's commencement of marketing a comprehe...
Read More...
Feb 28, 2024
Navigating the Evolving Landscape of Pharmacy Automation Solutions
Pharmacy Automation Systems represent a pivotal advancement in healthcare technology, revolutionizing the way medications are dispensed, managed, and administered. Over the years, these systems have evolved from rudimentary pill counters to sophisticated robotic dispensers and integrated software platforms. Moreove...
Read More...
Feb 27, 2024
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial; Dupixent sBLA Accepted for FDA Priority Review; Biogen’s QALSODY Received Positive Opinion from CHMP; FDA Granted Orphan Drug Designation to Immune-Onc’s IO-202; Artiva Biotherapeutics’s AlloNK® in Lupus Nephritis
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...
Read More...
Feb 26, 2024
Iovance’s Breakthrough: Amtagvi Paves the Way for Cell Therapies in Solid Tumors
The category of T-cell therapy, which revolutionized the management of specific blood cancers, has now extended its impact to solid tumor treatment with the approval from the FDA of a groundbreaking immunotherapy pioneered by Iovance Biotherapeutics. Known as Amtagvi or lifileucel, this medication marks the debut o...
Read More...
Feb 23, 2024
Ipsen’s Onivyde Combo Ends a Decade-Long Dry Spell in Newly Diagnosed Pancreatic Cancer
It marks the awaited green light for Ipsen following its acquisition of Onivyde in 2017. The FDA has given its nod to the supplemental new drug application for Onivyde (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as a primary treatment for adults with met...
Read More...
Feb 22, 2024
Johnson & Johnson’s Tecnis PureSee lens; Sparrow BioAcoustics’s Stethoscope Software; Better Therapeutics’s MASH Treatment; X-trodes’ Wearable “Skin” Solution; Lumicell’s LUMISIGHTTM; Konesksa Enrolled First Patient in Learns Observational Study
Johnson & Johnson, Launched New Intraocular Lens in EMEA Region On February 15, 2024, Johnson & Johnson Medtech’s vision unit launched the Tecnis PureSee lens in the EMEA region. Tecnis PureSee is a purely refractive intraocular lens (IOL) specifically designed to correct presbyopia. Its proprietary desi...
Read More...